ArticlePublic health weekly report2026
Korea 2024-2025 Influenza and Respiratory Virus Laboratory Surveillance Report.
Article in Public health weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study characterizes the detection patterns of respiratory viruses and the virological characteristics of influenza viruses in the Republic of Korea from week 36 of 2024 to week 35 of 2025, thereby contributing to evidence-based infection control policies and strengthening public health responses. Methods: Respiratory specimens were collected from patients with influenza-like illness at sentinel medical institutions and tested at 18 regional Institutes of Health and Environment. Molecular assays were conducted to detect respiratory viruses, and the distribution of etiologic agents was subsequently analyzed. The influenza viruses were further characterized through genetic, antigenic, and antiviral-resistance analyses to assess their similarity to the vaccine strains and susceptibility to antiviral agents. Results: Among specimens collected during the 2024-2025 season, influenza virus was the most frequently detected respiratory virus (15.2%), followed by rhinovirus (15.0%), severe acute respiratory syndrome coronavirus 2 (9.7%), parainfluenza virus (6.2%), adenovirus (4.9%), human metapneumovirus (4.8%), human coronavirus (4.7%), respiratory syncytial virus (3.6%), and human bocavirus (3.2%). The influenza virus subtypes included A(H1N1)pdm09 (39.6%), influenza B virus (36.8%), and A(H3N2) (23.6%). Circulating influenza viruses were genetically and antigenically similar to the 2024-2025 seasonal vaccine strains, and no antiviral-resistance mutations were detected. Conclusions: The epidemiology of influenza and other respiratory viruses varies across seasons, underscoring the importance of continuous surveillance to inform infection control policies and strengthen public health preparedness. Through the Korea Respiratory Virus Integrated Surveillance System, our division will continue to monitor the circulation of respiratory viruses and the characteristics of influenza viruses and disseminate these findings on an ongoing basis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.